Pharmaceuticals

Prostate Cancer Therapeutics Market Revenue Projected To Hit $14.79 Billion By 2030 With 7.3% CAGR

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Prostate Cancer Therapeutics Market During 2026–2030?

The prostate cancer therapeutics market size has observed substantial growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. The increase during the historical period is attributable to a rising incidence of prostate cancer, an aging male demographic, advancements in oncology drugs, the provision of hospital-based cancer care, and increased cancer screening efforts.

The prostate cancer therapeutics market is anticipated to show significant expansion in the coming years. Its size is projected to reach $19.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. This growth during the forecast period is propelled by factors such as the adoption of precision oncology, the emergence of biomarker-driven therapies, the rise in oral oncology drugs, an expanding pipeline of immunotherapies, and increased healthcare expenditure. Notable trends expected in this period involve the increasing uptake of targeted therapies, a rise in the use of PARP inhibitors, the broader application of immunotherapy in oncology, a transition towards oral cancer medications, and treatment selection guided by precision medicine.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Key Factors Are Affecting The Prostate Cancer Therapeutics Market Demand?

The increasing occurrence of prostate cancer is projected to drive the growth of the prostate cancer therapeutics market in the coming years. Prostate cancer is a condition where malignant cells develop within the tissues of the prostate gland, typically impacting older men. The incidence of prostate cancer is rising due to an aging population, as the risk of developing this disease substantially increases with age, and longer life expectancy means more men live long enough to be affected. Prostate cancer therapeutics aid in managing the disease by targeting cancer cells, decelerating its progression, and improving the quality of life through treatments such as surgery, radiation, hormone therapy, and contemporary alternatives like immunotherapy. For instance, in January 2025, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Therefore, the escalating incidence of prostate cancer is stimulating the expansion of the prostate cancer therapeutics market.

What Are The Main Segments Within The Prostate Cancer Therapeutics Market Segment Structure?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Which Trends Are Impacting The Progress Of The Prostate Cancer Therapeutics Market?

Leading companies within the prostate cancer therapeutics market are concentrating on developing advanced innovative treatments, such as an oral daily pill for advanced prostate cancer, to improve patient adherence and overall treatment results. This oral once-a-day pill for advanced prostate cancer refers to therapies designed for daily intake to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s impact on cancer cells. For example, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India’s first oral once-a-day pill containing relugolix for patients with advanced prostate cancer. This convenient and affordable substitute for injectable hormone therapies swiftly lowers testosterone, assisting in the control of cancer growth while also providing an enhanced cardiovascular safety profile. Being an oral therapy, it eliminates the requirement for injectable treatments that necessitate administration by healthcare providers, thus offering greater convenience for patients. This introduction marks a substantial progression in prostate cancer management in India, presenting patients and doctors with a novel, convenient, safe, and cost-effective therapeutic option.

Who Are The Companies Participating In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Get The Full Prostate Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Dominates The Prostate Cancer Therapeutics Market By Market Share?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Prostate Cancer Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795